First Sale Rule Eligibility: The 2026 Checklist for US Importers

The first sale rule under 19 CFR 152.103(a)(1) is one of the most underutilized duty-reduction tools in US customs valuation. Importers buying through a Hong Kong or Singapore middleman can elect to use the manufacturer-to-middleman price as the dutiable value, instead of the middleman-to-US price. The shift cuts the duty base by the middleman's markup, typically 20 to 40 percent. In 2026, with stacked duty rates frequently above 30 percent on Chinese goods and 20 percent on Asian lanes generally, the per-dollar duty saved by first-sale is at an all-time high.

This guide walks through the regulatory basis, the four-pillar eligibility test CBP audits today, the documentation that supports the claim, the worked savings math, and the common rejection scenarios.

Regulatory basis

19 CFR 152.103(a)(1) defines transaction value as "the price actually paid or payable for the merchandise when sold for exportation to the United States". The "sold for exportation" language has been interpreted by the courts (Nissho Iwai American Corp. v. United States, 982 F.2d 505) to permit the first sale in a multi-tier transaction structure to be used as the transaction value if the goods were clearly destined for the US at the time of that first sale.

The doctrine applies to multi-tier sales:

• Sale 1: manufacturer to middleman (often Hong Kong or Singapore trading house).
• Sale 2: middleman to US importer.

If the importer can prove that at the time of Sale 1 the goods were earmarked for the US, the importer may pay duty on the Sale 1 price.

The four-pillar eligibility test

CBP audits first-sale claims against four pillars. All four must be satisfied for the claim to survive.

Pillar 1: Bona fide arms-length first sale.

The manufacturer and the middleman must transact at arm's length. Related-party transactions (common ownership or control) trigger transfer pricing scrutiny. If related, the importer must demonstrate the transfer price approximates the price unrelated parties would have agreed.

Pillar 2: Goods destined for export to the US at the time of first sale.

The manufacturer's order, the production specifications, the labeling, and the shipping documents must all show the US as the ultimate destination at the time the manufacturer ships to the middleman. Generic "for export" orders that are later allocated to multiple country destinations do NOT qualify.

CBP looks for: US-specific labels printed at the factory, US-specific safety markings (UL, FCC, FDA), US-specific packaging (English text, US units of measure), shipping documents listing the US as the eventual destination.

Pillar 3: Documentation of the first sale.

The importer must hold and produce on demand:

• Manufacturer's invoice to the middleman, with line items, prices, and shipping terms.
• Proof of payment from middleman to manufacturer (bank wire confirmation, letter of credit settlement).
• Purchase order from the middleman to the manufacturer.
• Shipping documents from the manufacturer's factory.

The importer cannot rely on the middleman alone to retain these. CBP requires the importer to hold them as the entry filer.

Pillar 4: Related-party disclosure if applicable.

If the manufacturer and middleman are related (common ownership, parent-subsidiary, related individuals), the transfer price must be disclosed and documented as arms-length. CBP applies the same transfer pricing principles as the IRS, with valuation methods including comparable uncontrolled price, cost-plus, and resale margin.

Worked example: $1M Chinese consumer goods through Hong Kong

A US importer buys 1,000,000 USD of HTS 8517.62 from a Hong Kong trading house. The Hong Kong house bought from the Shenzhen manufacturer for 700,000 USD. Markup 300,000 USD, or 30 percent on cost (43 percent margin on sale).

Without first-sale election:

With first-sale election (dutiable value = 700,000 USD):

First-sale saving: 88,500 USD per shipment.

At quarterly shipment volume, annual saving exceeds 350,000 USD. The CBP audit risk is real but the documentation cost (legal review, holding the manufacturer invoices) is typically 20,000 to 50,000 USD per year.

The pillars in practice

Pillar 1 (arms-length). Most Hong Kong trading houses are independent from the Shenzhen manufacturers they buy from. CBP rarely contests pillar 1 in unrelated-party setups. Related-party (common-owned) setups fail pillar 1 unless the transfer pricing is documented to OECD standards.

Pillar 2 (destined for US). The hardest pillar. Manufacturers must accept US-specific labels and packaging at the factory, even when shipping to a Hong Kong warehouse first. If the goods are commingled with non-US orders at the factory and split later, the destined-for-US claim fails.

A common operating fix: the importer issues a US-specific spec sheet that the manufacturer follows for the production run, including labels and packaging. The spec sheet is dated before the manufacturer's invoice. The chain of custody can be traced from spec to invoice to shipment.

Pillar 3 (documentation). Requires the importer to actually obtain the manufacturer invoices. Many middlemen resist sharing because the markup becomes visible. The importer's leverage is the volume of business; the middleman wants the recurring order.

Pillar 4 (related parties). If the chain is manufacturer-to-middleman-to-importer and the importer's parent owns the middleman, all three are effectively related. The transfer pricing analysis must justify both the manufacturer-to-middleman price and the middleman-to-importer price. Significant documentation cost.

When first sale does NOT work

• When the importer buys directly from the manufacturer without a middleman. There is no first sale to elect.
• When the middleman performs substantial processing (assembly, repackaging, labeling). The manufacturer-to-middleman product is not the same as the middleman-to-importer product.
• When the goods are sold under a contract that bundles multiple country destinations and the US allocation is decided later.
• When the manufacturer's invoice prices are confidential commercial terms the middleman will not share.

Audit posture in 2026

CBP has tightened first-sale audit posture from 2023 onward, focused on three failure modes:

1. Manufacturer invoices that show the price denominated in the middleman's currency without a clear price-to-US connection.
2. Generic export orders that get reallocated to US after manufacture.
3. Related-party setups without OECD-standard transfer pricing documentation.

The 2026 audit cycle is processing entries from 2023 to 2024. Entries filed in 2026 will face audits in 2028 to 2029. Build the documentation now.

Run your first-sale analysis now

The LandedFees calculator includes a first-sale-eligibility checker. Provide the manufacturer-to-middleman price alongside the middleman-to-US price and the engine returns the duty saving, the four-pillar status (presumed compliant unless flagged), and the audit-risk exposure summary.

Calculate a first-sale entry

Section 122 status as of June 20 2026

The May 7 2026 Court of International Trade ruling in Oregon v. United States (consolidated with Burlap and Barrel v. United States) struck down the Section 122 proclamation. The Federal Circuit issued an administrative stay on May 12 2026, so CBP is still collecting the duty pending appeal. Importers paying now should preserve protest rights and refund claims in case the government loses on the merits. The underlying Section 122 authority sunsets July 24 2026 under the statutory 150-day ceiling, regardless of the appeal outcome, unless Congress extends or a fresh proclamation restarts the clock.

Citations

• 19 CFR 152.103(a)(1): https://www.ecfr.gov/current/title-19/chapter-I/part-152/section-152.103
• Nissho Iwai American Corp. v. United States, 982 F.2d 505 (Fed Cir 1992)
• CBP Informed Compliance Publication on transaction value: https://www.cbp.gov/document/publications/customs-valuation-encyclopedia
• 19 USC 1592 (penalties for valuation negligence or fraud)
• CBP Focused Assessment audit procedures: CBP Trade Regulatory Audit